150 related articles for article (PubMed ID: 20601161)
1. Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus.
Hennekens CH; Hebert PR; Schneider WR; O'Brien P; Demets D; Borer JS
Contemp Clin Trials; 2010 Sep; 31(5):411-3. PubMed ID: 20601161
[TBL] [Abstract][Full Text] [Related]
2. Model-based benefit-risk assessment: can Archimedes help?
Krishna R
Clin Pharmacol Ther; 2009 Mar; 85(3):239-40. PubMed ID: 19223878
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
4. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
[TBL] [Abstract][Full Text] [Related]
5. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
[TBL] [Abstract][Full Text] [Related]
6. Finding value in the U.S. Food and Drug Administration's Fast Track program.
Reichert JM; Rochon SL; Zhang BD
Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
[TBL] [Abstract][Full Text] [Related]
7. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
Wright C; Schnoll S; Bernstein D
Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
[TBL] [Abstract][Full Text] [Related]
8. The socio-political roots of pharmaceutical uncertainty in the evaluation of 'innovative' diabetes drugs in the European Union and the US.
Davis C; Abraham J
Soc Sci Med; 2011 May; 72(9):1574-81. PubMed ID: 21474222
[TBL] [Abstract][Full Text] [Related]
9. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
10. Considerations for design and data analysis of noninferiority/superiority cardiovascular trials.
Quan H; Li M; Zhao PL; Cho M; Zhang J; Wu Y
J Biopharm Stat; 2013; 23(1):239-60. PubMed ID: 23331234
[TBL] [Abstract][Full Text] [Related]
11. Innovative early development regulatory approaches: expIND, expCTA, microdosing.
Robinson WT
Clin Pharmacol Ther; 2008 Feb; 83(2):358-60. PubMed ID: 18091759
[TBL] [Abstract][Full Text] [Related]
12. Drug safety. Planned study of Avandia in doubt after FDA review.
Kean S
Science; 2010 Jul; 329(5990):375. PubMed ID: 20651123
[No Abstract] [Full Text] [Related]
13. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
14. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
15. Innovative strategies for early clinical R&D.
Butz RF; Morelli G
IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications.
Hoogwerf BJ; Manner DH; Fu H; Moscarelli E; Gaydos BL; Heine RJ
Diabetes Care; 2016 Aug; 39 Suppl 2():S219-27. PubMed ID: 27440836
[TBL] [Abstract][Full Text] [Related]
17. The UGDP and the FDA audit.
Am Fam Physician; 1979 Jul; 20(1):67. PubMed ID: 377929
[No Abstract] [Full Text] [Related]
18. Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development.
Hwang TJ; Franklin JM; Kesselheim AS
Clin Pharmacol Ther; 2017 Aug; 102(2):290-296. PubMed ID: 28390139
[TBL] [Abstract][Full Text] [Related]
19. Cautious welcome for FDA pharmacogenomics guidance.
Katsnelson A;
Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
[No Abstract] [Full Text] [Related]
20. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke.
Feuerstein GZ; Zaleska MM; Krams M; Wang X; Day M; Rutkowski JL; Finklestein SP; Pangalos MN; Poole M; Stiles GL; Ruffolo RR; Walsh FL
J Cereb Blood Flow Metab; 2008 Jan; 28(1):217-9. PubMed ID: 17579658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
